Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
Curr Med Chem. 2021;28(25):5137-5151. doi: 10.2174/0929867328666201207202012.
Breast cancer is the most common malignant tumor in women worldwide. Traditional ways of treatment, including radiotherapy and endocrine therapy, for breast cancer have inevitable side effects. In recent decades, targeted therapies for breast cancer have rapidly advanced and shown a promising future. The JAK/STAT signaling pathway has been shown to play important roles in tumorigenesis, maintenance and metastasis of breast cancer. Hence, many small molecule inhibitors of JAK and STAT proteins have been developed. These inhibitors exhibit potent inhibitory effects on breast cancer in both cellular and animal models, and even some of them have already been in clinical trials. This review article discussed the JAK/STAT signal transduction pathway in the pathogenesis of breast cancer, and the potential for the application of JAK/STAT inhibitors in breast cancer treatment.
乳腺癌是全球女性最常见的恶性肿瘤。乳腺癌的传统治疗方法，包括放疗和内分泌治疗，都有不可避免的副作用。近几十年来，乳腺癌的靶向治疗迅速发展，展现出广阔的前景。JAK/STAT 信号通路已被证明在乳腺癌的发生、维持和转移中发挥着重要作用。因此，已经开发出许多 JAK 和 STAT 蛋白的小分子抑制剂。这些抑制剂在细胞和动物模型中对乳腺癌均表现出强大的抑制作用，甚至其中一些已经在临床试验中。本文讨论了 JAK/STAT 信号转导通路在乳腺癌发病机制中的作用，以及 JAK/STAT 抑制剂在乳腺癌治疗中的应用潜力。
